Clinical Trials Logo

LDL Hyperlipoproteinemia clinical trials

View clinical trials related to LDL Hyperlipoproteinemia.

Filter by:
  • None
  • Page 1

NCT ID: NCT06154408 Completed - Clinical trials for Low-Density-Lipoprotein-Type [LDL] Hyperlipoproteinemia

Evaluating the Impact of Omega-3 Fatty Acid Supplementation (Soloways™) on Lipid Profiles in Adults With PPARG Polymorphisms

SOLIPARG
Start date: February 10, 2022
Phase: N/A
Study type: Interventional

In this study, 102 patients will be evenly randomized into two groups: one set to receive omega-3 fatty acids and the other a placebo. The process will be blinded, ensuring that neither the researchers nor the participants will know which group they are in. Each participant will take two capsules daily for a duration of 90 days, with the active group receiving capsules containing 1000 mg of fish oil each. All participants will be instructed to maintain their usual diet, lifestyle, and medication regimen. At the beginning and end of the study, various health assessments, including lipid panels and C-reactive protein measurements, will be conducted. Additionally, DNA samples will be collected for genotyping to identify patients with specific PPARG gene polymorphisms, leading to the creation of four distinct subgroups: those receiving omega-3 with and without polymorphisms, and those receiving placebo with and without polymorphisms.

NCT ID: NCT04330209 Completed - Weight Loss Clinical Trials

Comparing a Low-GI Nutrigenetic and Ketogenic Diet for Weight Loss With 18 Month Follow-up

LOWGI_GENE
Start date: January 1, 2014
Phase:
Study type: Observational

The investigators followed a convenience sample of 114 overweight and obese subjects from a weight loss clinic who followed a 24-week dietary intervention. The subjects self-selected whether to follow a standardized ketogenic diet (n=53), or a personalised low-glycemic index (GI) diet utilising information from 28 single nucleotide polymorphisms (n=61). After the 24-week study period, the subjects were monitored for an additional 18 months.

NCT ID: NCT03607383 Recruiting - Dyslipidemias Clinical Trials

Red Rice Yeast in Low-density Lipoprotein (LDL) Lowering: an Efficacy Study

Start date: February 7, 2018
Phase: Phase 2
Study type: Interventional

Red yeast rice is a source of active compounds in reducing LDL levels with practically no side effects. Molval Fort is a natural product available in the Lebanese market with a combination of red yeast rice extracts, EPA/DHA and coenzyme Q10. The investigators are conducting this study to explore the effect of red yest rice extracts based product on LDL and its side effects in a sample of primary care Lebanese patients.